16.7 0.05 (0.3%) | 01-23 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 19.52 | 1-year : | 22.8 |
Resists | First : | 16.71 | Second : | 19.52 |
Pivot price | 16.63 | |||
Supports | First : | 16.5 | Second : | 16.37 |
MAs | MA(5) : | 16.7 | MA(20) : | 16.57 |
MA(100) : | 14.65 | MA(250) : | 8.92 | |
MACD | MACD : | 0.1 | Signal : | 0.1 |
%K %D | K(14,3) : | 93.9 | D(3) : | 93.9 |
RSI | RSI(14): 85.3 | |||
52-week | High : | 16.71 | Low : | 4.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ORTX ] has closed below upper band by 32.9%. Bollinger Bands are 85.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 68 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 16.74 - 16.82 | 16.82 - 16.89 |
Low: | 16.47 - 16.58 | 16.58 - 16.67 |
Close: | 16.54 - 16.71 | 16.71 - 16.85 |
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Thu, 25 Jan 2024
Orchard Therapeutics Acquired by Kyowa Kirin - TipRanks.com - TipRanks
Thu, 25 Jan 2024
Orchard Therapeutics ADSs Delisting from Nasdaq - TipRanks.com - TipRanks
Wed, 24 Jan 2024
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases - Yahoo Finance
Fri, 19 Jan 2024
Orchard Therapeutics (ORTX): Still An Attractive Merger Arbitrage Opportunity - Seeking Alpha
Tue, 28 Nov 2023
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire
Mon, 13 Nov 2023
Orchard Therapeutics PLC (ORTX) Reports Q3 2023 Earnings and Announces Acquisition by Kyowa Kirin - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 23 (M) |
Shares Float | 118 (M) |
Held by Insiders | 12.2 (%) |
Held by Institutions | 103.5 (%) |
Shares Short | 31 (K) |
Shares Short P.Month | 41 (K) |
EPS | -4.1 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 3.52 |
Profit Margin | 0 % |
Operating Margin | -342.9 % |
Return on Assets (ttm) | -29.3 % |
Return on Equity (ttm) | -71.5 % |
Qtrly Rev. Growth | 9.1 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.95 |
EBITDA (p.s.) | -4.37 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -93 (M) |
Levered Free Cash Flow | -50 (M) |
PE Ratio | -4.08 |
PEG Ratio | 0 |
Price to Book value | 4.73 |
Price to Sales | 17.4 |
Price to Cash Flow | -4.08 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |